Reprogramming gene expression via genetic or epigenetic perturbation of transcriptional control elements has emerged as a major mechanism of oncogenesis. Using a comparative omics approach, we have defined pathogenic regulatory circuits in primary B cell tumors (follicular lymphoma, FL), linking dysfunctional enhancers to their target genes, including many involved in cellular transformation. Remarkably, a significant number of FLAREs overlap lymphoma-associated SNPs or have acquired mutations that impact enhancer function. Our epigenome-centric approach also revealed two previously unappreciated FL subtypes whose signature genes correlate with subclass-specific FLAREs. These discoveries establish distinct cistrome-based etiologies for FL and provide targets for personalized epigenetic therapies. In this regard, we have developed an innovative strategy to target pathogenic REs for reversal, using sequence-specific DNA binding proteins tethered to chromatin modifiers (termed SSCMs). Using a prototype SSCM composed of a zinc-finger (ZF) protein fused to a KRAB repressor domain, we have targeted BCL6, a key NHL oncogene, reversing its pathogenic expression and causing widespread cell death. The goal of our proposal is the development of targeted epigenetic therapeutics for NHL that can be delivered as proteins in vivo. This translational approach targets tumor-specific REs, avoiding the side effects of broad-spectrum epigenetic inhibitors.
In Aim 1, FLAREs that regulate multiple cancer-associated genes will be selected by integrating bioinformatic analyses with high-throughput assays of enhancer function. These multi-genic REs, or control hubs, are attractive therapeutic targets because reversal of their aberrant function will impact the expression of several genes simultaneously, reducing the potential for tumor escape.
In Aim 2, we will develop SSCMs to target these control hubs by optimizing combinations of sequence-specific domains (zinc fingers, TALEs) and chromatin modifiers (activating or repressing). In parallel, we will develop targeted nanocarrier approaches designed to improve SSCM delivery and efficacy by binding to surface markers on NHL or neovasculature in the tumor microenvironment.
Aim 3 studies will utilize a mouse xenograft model of NHL to compare direct protein delivery of SSCMs with targeted nanocarrier platforms tested in Aim 2, to maximize therapeutic efficacy while minimizing immunogenicity and off-target effects in normal cells. To accomplish our goals, the applicants have assembled a team of basic, clinical and bioinformatics researchers who have been collaborating productively for several years on the foundational aspects of this problem, defining the cistrome-based etiology of NHL. Collectively, this work is expected to have an impact well beyond NHL, shepherding the use of targeted epigenetic therapies to reverse pathogenic changes in regulatory elements that mediate many cancers.

Public Health Relevance

Understanding the epigenetic basis of gene expression will provide new opportunities for therapeutic intervention in human disease because, unlike genetic lesions, pathogenic changes to the epigenome are reversible. We have discovered a set of novel regulatory elements that alter the epigenome of non-Hodgkin lymphoma (NHL), driving tumor-specific changes in gene expression. We propose an innovative strategy to reverse these aberrations in gene expression by targeting the regulatory elements with sequence-specific modifiers of the epigenome that are packaged in custom NHL-seeking nanoparticles.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA188286-04
Application #
9477494
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Kondapaka, Sudhir B
Project Start
2015-05-01
Project End
2020-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Washington University
Department
Pathology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Andrews, Jared M; Payton, Jacqueline E (2018) Epigenetic dynamics in normal and malignant B cells: die a hero or live to become a villain. Curr Opin Immunol 57:15-22
Huang, Yue; Koues, Olivia I; Zhao, Jiang-Yang et al. (2017) cis-Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent. Cell Rep 18:2918-2931
Luo, Hong; Schmidt, Jennifer A; Lee, Yi-Shan et al. (2017) Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL. Leuk Lymphoma 58:445-456
Zhao, Jiang-Yang; Osipovich, Oleg; Koues, Olivia I et al. (2017) Activation of Mouse Tcrb: Uncoupling RUNX1 Function from Its Cooperative Binding with ETS1. J Immunol 199:1131-1141
Gu, Junchen; Stevens, Michael; Xing, Xiaoyun et al. (2016) Mapping of Variable DNA Methylation Across Multiple Cell Types Defines a Dynamic Regulatory Landscape of the Human Genome. G3 (Bethesda) 6:973-86
Koues, Olivia I; Collins, Patrick L; Cella, Marina et al. (2016) Distinct Gene Regulatory Pathways for Human Innate versus Adaptive Lymphoid Cells. Cell 165:1134-1146
Koues, Olivia I; Oltz, Eugene M; Payton, Jacqueline E (2015) Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma. Trends Genet 31:720-731